Antibiotics, gut microbiota, environment in early life and type 1 diabetes

Pharmacological Research

Volumn 119, Issue , 2017, Pages 219-226

  Hu, Youjia ^a   Wong, F Susan ^b   Wen, Li ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Gut microbiota; Immune regulation; Neonatal immune response; Type 1 diabetes

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; GENTAMICIN; MEROPENEM; METRONIDAZOLE; NEOMYCIN; PENICILLIN V; POLYMYXIN B; STREPTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIGEN PRESENTING CELL; BACTERIAL COLONIZATION; BACTERIAL IMMUNITY; BACTEROIDES; BIFIDOBACTERIUM; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; KLEBSIELLA; LACTOBACILLUS; LEPTOTRICHIA; MICROBIAL COMMUNITY; NONHUMAN; REVIEW; STREPTOCOCCUS; T LYMPHOCYTE; ANIMAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FECES; GASTROINTESTINAL TRACT; IMMUNE SYSTEM; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; DIABETES MELLITUS, TYPE 1; FECES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE;

EID: 85013001574     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.01.034     Document Type: Review

References (123)

1. [1] Babaya, N., Nakayama, M., Eisenbarth, G.S., The stages of type 1A diabetes. Ann. N. Y. Acad. Sci. 1051 (2005), 194–204.
2. [2] Bluestone, J.A., Herold, K., Eisenbarth, G., Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:7293 (2010), 1293–1300.
3. [3] Metcalfe, K.A., Hitman, G.A., Rowe, R.E., Hawa, M., Huang, X., Stewart, T., Leslie, R.D., Concordance for type 1 diabetes in identical twins is affected by insulin genotype. Diabetes Care 24:5 (2001), 838–842.
4. [4] Redondo, M.J., Yu, L., Hawa, M., Mackenzie, T., Pyke, D.A., Eisenbarth, G.S., Leslie, R.D., Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 44:3 (2001), 354–362.
5. [5] Todd, J.A., Walker, N.M., Cooper, J.D., Smyth, D.J., Downes, K., Plagnol, V., Bailey, R., Nejentsev, S., Field, S.F., Payne, F., Lowe, C.E., Szeszko, J.S., Hafler, J.P., Zeitels, L., Yang, J.H., Vella, A., Nutland, S., Stevens, H.E., Schuilenburg, H., Coleman, G., Maisuria, M., Meadows, W., Smink, L.J., Healy, B., Burren, O.S., Lam, A.A., Ovington, N.R., Allen, J., Adlem, E., Leung, H.T., Wallace, C., Howson, J.M., Guja, C., Ionescu-Tirgoviste, C., Simmonds, M.J., Heward, J.M., Gough, S.C., Dunger, D.B., Wicker, L.S., Clayton, D.G., Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39:7 (2007), 857–864.
6. [6] Todd, J.A., Bell, J.I., McDevitt HO: HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329:6140 (1987), 599–604.
7. [7] Achenbach, P., Bonifacio, E., Koczwara, K., Ziegler, A.G., Natural history of type 1 diabetes. Diabetes 54:Suppl. 2 (2005), S25–31.
8. [8] Patterson, C.C., Gyurus, E., Rosenbauer, J., Cinek, O., Neu, A., Schober, E., Parslow, R.C., Joner, G., Svensson, J., Castell, C., Bingley, P.J., Schoenle, E., Jarosz-Chobot, P., Urbonaite, B., Rothe, U., Krzisnik, C., Ionescu-Tirgoviste, C., Weets, I., Kocova, M., Stipancic, G., Samardzic, M., de Beaufort, C.E., Green, A., Dahlquist, G.G., Soltesz, G., Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase. Diabetologia 55:8 (2012), 2142–2147.
9. [9] Knip, M., Veijola, R., Virtanen, S.M., Hyoty, H., Vaarala, O., Akerblom, H.K., Environmental triggers and determinants of type 1 diabetes. Diabetes 54:Suppl. 2 (2005), S125–136.
10. [10] Knip, M., Simell, O., Environmental triggers of type 1 diabetes. Cold Spring Harb. Perspect. Med., 2(7), 2012, a007690.
11. [11] Wen, L., Ley, R.E., Volchkov, P.Y., Stranges, P.B., Avanesyan, L., Stonebraker, A.C., Hu, C., Wong, F.S., Szot, G.L., Bluestone, J.A., Gordon, J.I., Chervonsky, A.V., Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455:7216 (2008), 1109–1113.
12. [12] Cerf-Bensussan, N., Gaboriau-Routhiau, V., The immune system and the gut microbiota: friends or foes?. Nat. Rev. Immunol. 10:10 (2010), 735–744.
13. [13] Round, J.L., Mazmanian, S.K., The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9:5 (2009), 313–323.
14. [14] Tai, N., Wong, F.S., Wen, L., The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev. Endocr. Metab. Disord. 16:1 (2015), 55–65.
15. [15] Llorente, C., Schnabl, B., The gut microbiota and liver disease. Cell Mol. Gastroenterol. Hepatol. 1:3 (2015), 275–284.
16. [16] Goto, Y., Kurashima, Y., Kiyono, H., The gut microbiota and inflammatory bowel disease. Curr. Opin. Rheumatol. 27:4 (2015), 388–396.
17. [17] Vital, M., Harkema, J.R., Rizzo, M., Tiedje, J., Brandenberger, C., Alterations of the murine gut microbiome with age and allergic irway disease. J. Immunol. Res., 2015, 2015, 892568.
18. [18] Zhao, Y., Lukiw, W.J., Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer's disease (AD). J. Nat. Sci., 1(7), 2015, e138.
19. [19] Johnson, B.M., Gaudreau, M.C., Al-Gadban, M.M., Gudi, R., Vasu, C., Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone SNF1 mice. Clin. Exp. Immunol. 181:2 (2015), 323–337.
20. [20] Verbeke, K.A., Boesmans, L., Boets, E., Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?. Proc. Nutr. Soc. 73:4 (2014), 490–497.
21. [21] Walujkar, S.A., Dhotre, D.P., Marathe, N.P., Lawate, P.S., Bharadwaj, R.S., Shouche, Y.S., Characterization of bacterial community shift in human Ulcerative Colitis patients revealed by Illumina based 16S rRNA gene amplicon sequencing. Gut Pathog., 6, 2014, 22.
22. [22] Wu, H.J., Ivanov, I.I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D.R., Benoist, C., Mathis, D., Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32:6 (2010), 815–827.
23. [23] Alkanani, A.K., Hara, N., Gottlieb, P.A., Ir, D., Robertson, C.E., Wagner, B.D., Frank, D.N., Zipris, D., Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes 64:10 (2015), 3510–3520.
24. [24] Burrows, M.P., Volchkov, P., Kobayashi, K.S., Chervonsky, A.V., Microbiota regulates type 1 diabetes through toll-like receptors. Proc. Natl. Acad. Sci. U. S. A. 112:32 (2015), 9973–9977.
25. [25] Hu, Y., Peng, J., Tai, N., Hu, C., Zhang, X., Wong, F.S., Wen, L., Maternal antibiotic treatment protects offspring from diabetes development in nonobese diabetic mice by generation of tolerogenic APCs. J. Immunol. 195:9 (2015), 4176–4184.
26. [26] Peng, J., Narasimhan, S., Marchesi, J.R., Benson, A., Wong, F.S., Wen, L., Long term effect of gut microbiota transfer on diabetes development. J. Autoimmun. 53 (2014), 85–94.
27. [27] Hu, Y., Jin, P., Peng, J., Zhang, X., Wong, F.S., Wen, L., Different immunological responses to early-life antibiotic exposure affecting autoimmune diabetes development in NOD mice. J. Autoimmun. 72 (2016), 47–56.
28. [28] Pearson, J.A., Wong, F.S., Wen, L., The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J. Autoimmun. 66 (2016), 76–88.
29. [29] Galipeau, H.J., McCarville, J.L., Huebener, S., Litwin, O., Meisel, M., Jabri, B., Sanz, Y., Murray, J.A., Jordana, M., Alaedini, A., Chirdo, F.G., Verdu, E.F., Intestinal microbiota modulates gluten-induced immunopathology in humanized mice. Am. J. Pathol. 185:11 (2015), 2969–2982.
30. [30] Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., Cullender, T.C., Mwangi, S., Srinivasan, S., Sitaraman, S.V., Knight, R., Ley, R.E., Gewirtz, A.T., Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science 328:5975 (2010), 228–231.
31. [31] Horai, R., Zarate-Blades, C.R., Dillenburg-Pilla, P., Chen, J., Kielczewski, J.L., Silver, P.B., Jittayasothorn, Y., Chan, C.C., Yamane, H., Honda, K., Caspi, R.R., Microbiota-dependent activation of an autoreactive t cell receptor provokes autoimmunity in an immunologically privileged site. Immunity 43:2 (2015), 343–353.
32. [32] Macpherson, A.J., Uhr, T., Compartmentalization of the mucosal immune responses to commensal intestinal bacteria. Ann. N. Y. Acad. Sci. 1029 (2004), 36–43.
33. [33] Stecher, B., Hardt, W.D., Mechanisms controlling pathogen colonization of the gut. Curr. Opin. Microbiol. 14:1 (2011), 82–91.
34. [34] Natividad, J.M., Petit, V., Huang, X., de Palma, G., Jury, J., Sanz, Y., Philpott, D., Garcia Rodenas, C.L., McCoy, K.D., Verdu, E.F., Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice. Inflamm. Bowel Dis. 18:8 (2012), 1434–1446.
35. [35] Kim, Y.S., Ho, S.B., Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr. Gastroenterol. Rep. 12:5 (2010), 319–330.
36. [36] Dave, M., Higgins, P.D., Middha, S., Rioux, K.P., The human gut microbiome: current knowledge, challenges, and future directions. Transl. Res. 160:4 (2012), 246–257.
37. [37] Dominguez-Bello, M.G., Blaser, M.J., Ley, R.E., Knight, R., Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 140:6 (2011), 1713–1719.
38. [38] Kriegel, M.A., Sefik, E., Hill, J.A., Wu, H.J., Benoist, C., Mathis, D., Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 108:28 (2011), 11548–11553.
39. [39] Lau, K., Benitez, P., Ardissone, A., Wilson, T.D., Collins, E.L., Lorca, G., Li, N., Sankar, D., Wasserfall, C., Neu, J., Atkinson, M.A., Shatz, D., Triplett, E.W., Larkin, J. 3rd, Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. J. Immunol. 186:6 (2011), 3538–3546.
40. [40] Satoh, J., Shintani, S., Oya, K., Tanaka, S., Nobunaga, T., Toyota, T., Goto, Y., Treatment with streptococcal preparation (OK-432) suppresses anti-islet autoimmunity and prevents diabetes in BB rats. Diabetes 37:9 (1988), 1188–1194.
41. [41] Sai, P., Rivereau, A.S., Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabetes Metab. 22:5 (1996), 341–348.
42. [42] Alam, C., Bittoun, E., Bhagwat, D., Valkonen, S., Saari, A., Jaakkola, U., Eerola, E., Huovinen, P., Hanninen, A., Effects of a germ-free environment on gut immune regulation and diabetes progression in non-obese diabetic (NOD) mice. Diabetologia 54:6 (2011), 1398–1406.
43. [43] King, C., Sarvetnick, N., The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions. PLoS One, 6(2), 2011, e17049.
44. [44] Bach, J.F., Chatenoud, L., The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes. Cold Spring Harb. Perspect. Med., 2(2), 2012, a007799.
45. [45] Vatanen, T., Kostic, A.D., d'Hennezel, E., Siljander, H., Franzosa, E.A., Yassour, M., Kolde, R., Vlamakis, H., Arthur, T.D., Hamalainen, A.M., Peet, A., Tillmann, V., Uibo, R., Mokurov, S., Dorshakova, N., Ilonen, J., Virtanen, S.M., Szabo, S.J., Porter, J.A., Lahdesmaki, H., Huttenhower, C., Gevers, D., Cullen, T.W., Knip, M., Group, D.S., Xavier, R.J., Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 165:4 (2016), 842–853.
46. [46] Tai, N., Peng, J., Liu, F., Gulden, E., Hu, Y., Zhang, X., Chen, L., Wong, F.S., Wen, L., Microbial antigen mimics activate diabetogenic CD8 T cells in NOD mice. J. Exp. Med. 213:10 (2016), 2129–2146.
47. [47] Li, X., Atkinson, M.A., The role for gut permeability in the pathogenesis of type 1 diabetes – a solid or leaky concept?. Pediatr. Diabetes 16:7 (2015), 485–492.
48. [48] de Kort, S., Keszthelyi, D., Masclee, A.A., Leaky gut and diabetes mellitus: what is the link?. Obes. Rev. 12:6 (2011), 449–458.
49. [49] Liu, Z., Li, N., Neu, J., Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr. 94:4 (2005), 386–393.
50. [50] Kostic, A.D., Gevers, D., Siljander, H., Vatanen, T., Hyotylainen, T., Hamalainen, A.M., Peet, A., Tillmann, V., Poho, P., Mattila, I., Lahdesmaki, H., Franzosa, E.A., Vaarala, O., de Goffau, M., Harmsen, H., Ilonen, J., Virtanen, S.M., Clish, C.B., Oresic, M., Huttenhower, C., Knip, M., Xavier, R.J., The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe 17:2 (2015), 260–273.
51. [51] Kupila, A., Muona, P., Simell, T., Arvilommi, P., Savolainen, H., Hamalainen, A.M., Korhonen, S., Kimpimaki, T., Sjoroos, M., Ilonen, J., Knip, M., Simell, O., Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia 44:3 (2001), 290–297.
52. [52] Hansen, C.H., Krych, L., Nielsen, D.S., Vogensen, F.K., Hansen, L.H., Sorensen, S.J., Buschard, K., Hansen, A.K., Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 55:8 (2012), 2285–2294.
53. [53] Tormo-Badia, N., Hakansson, A., Vasudevan, K., Molin, G., Ahrne, S., Cilio, C.M., Antibiotic treatment of pregnant non-obese diabetic mice leads to altered gut microbiota and intestinal immunological changes in the offspring. Scand. J. Immunol. 80:4 (2014), 250–260.
54. [54] Lammi, N., Karvonen, M., Tuomilehto, J., Do microbes have a causal role in type 1 diabetes?. Med. Sci. Monit. 11:3 (2005), RA63–69.
55. [55] Alyanakian, M.A., Grela, F., Aumeunier, A., Chiavaroli, C., Gouarin, C., Bardel, E., Normier, G., Chatenoud, L., Thieblemont, N., Bach, J.F., Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 55:1 (2006), 179–185.
56. [56] Korsgren, S., Molin, Y., Salmela, K., Lundgren, T., Melhus, A., Korsgren, O., On the etiology of type 1 diabetes: a new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response. Am. J. Pathol. 181:5 (2012), 1735–1748.
57. [57] Peraneva, L., Fogarty, C.L., Pussinen, P.J., Forsblom, C., Groop, P.H., Lehto, M., Systemic exposure to Pseudomonal bacteria: a potential link between type 1 diabetes and chronic inflammation. Acta Diabetol. 50:3 (2013), 351–361.
58. [58] Clarke, T.B., Davis, K.M., Lysenko, E.S., Zhou, A.Y., Yu, Y., Weiser, J.N., Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 16:2 (2010), 228–231.
59. [59] Patrick, C., Wang, G.S., Lefebvre, D.E., Crookshank, J.A., Sonier, B., Eberhard, C., Mojibian, M., Kennedy, C.R., Brooks, S.P., Kalmokoff, M.L., Maglio, M., Troncone, R., Poussier, P., Scott, F.W., Promotion of autoimmune diabetes by cereal diet in the presence or absence of microbes associated with gut immune activation, regulatory imbalance, and altered cathelicidin antimicrobial peptide. Diabetes 62:6 (2013), 2036–2047.
60. [60] Candon, S., Perez-Arroyo, A., Marquet, C., Valette, F., Foray, A.P., Pelletier, B., Milani, C., Ventura, M., Bach, J.F., Chatenoud, L., Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. PLoS One, 10(5), 2015, e0125448.
61. [61] Brown, K., Godovannyi, A., Ma, C., Zhang, Y., Ahmadi-Vand, Z., Dai, C., Gorzelak, M.A., Chan, Y., Chan, J.M., Lochner, A., Dutz, J.P., Vallance, B.A., Gibson, D.L., Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. ISME J. 10:2 (2016), 321–332.
62. [62] Crider, K.S., Cleves, M.A., Reefhuis, J., Berry, R.J., Hobbs, C.A., Hu, D.J., Antibacterial medication use during pregnancy and risk of birth defects: national birth defects prevention study. Arch. Pediatr. Adolesc. Med. 163:11 (2009), 978–985.
63. [63] Card, R.M., Mafura, M., Hunt, T., Kirchner, M., Weile, J., Rashid, M.U., Weintraub, A., Nord, C.E., Anjum, M.F., Impact of ciprofloxacin and clindamycin administration on gram-negative bacteria isolated from healthy volunteers and characterization of the resistance genes they harbor. Antimicrob. Agents Chemother. 59:8 (2015), 4410–4416.
64. [64] Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N., Knight, R., Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. U. S. A. 107:26 (2010), 11971–11975.
65. [65] Brugman, S., Klatter, F.A., Visser, J.T., Wildeboer-Veloo, A.C., Harmsen, H.J., Rozing, J., Bos, N.A., Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes?. Diabetologia 49:9 (2006), 2105–2108.
66. [66] Visser, J.T., Bos, N.A., Harthoorn, L.F., Stellaard, F., Beijer-Liefers, S., Rozing, J., van Tol, E.A., Potential mechanisms explaining why hydrolyzed casein-based diets outclass single amino acid-based diets in the prevention of autoimmune diabetes in diabetes-prone BB rats. Diabetes Metab. Res. Rev. 28:6 (2012), 505–513.
67. [67] Roesch, L.F., Lorca, G.L., Casella, G., Giongo, A., Naranjo, A., Pionzio, A.M., Li, N., Mai, V., Wasserfall, C.H., Schatz, D., Atkinson, M.A., Neu, J., Triplett, E.W., Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J. 3:5 (2009), 536–548.
68. [68] de Goffau, M.C., Luopajarvi, K., Knip, M., Ilonen, J., Ruohtula, T., Harkonen, T., Orivuori, L., Hakala, S., Welling, G.W., Harmsen, H.J., Vaarala, O., Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes 62:4 (2013), 1238–1244.
69. [69] Murri, M., Leiva, I., Gomez-Zumaquero, J.M., Tinahones, F.J., Cardona, F., Soriguer, F., Queipo-Ortuno, M.I., Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med., 11, 2013, 46.
70. [70] Thompson, C.L., Vier, R., Mikaelyan, A., Wienemann, T., Brune, A., ‘Candidatus Arthromitus’ revised: segmented filamentous bacteria in arthropod guts are members of Lachnospiraceae. Environ. Microbiol. 14:6 (2012), 1454–1465.
71. [71] Ivanov, I.I., Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K.C., Santee, C.A., Lynch, S.V., Tanoue, T., Imaoka, A., Itoh, K., Takeda, K., Umesaki, Y., Honda, K., Littman, D.R., Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:3 (2009), 485–498.
72. [72] Yurkovetskiy, L., Burrows, M., Khan, A.A., Graham, L., Volchkov, P., Becker, L., Antonopoulos, D., Umesaki, Y., Chervonsky, A.V., Gender bias in autoimmunity is influenced by microbiota. Immunity 39:2 (2013), 400–412.
73. [73] Bolotin, A., de Wouters, T., Schnupf, P., Bouchier, C., Loux, V., Rhimi, M., Jamet, A., Dervyn, R., Boudebbouze, S., Blottiere, H.M., Sorokin, A., Snel, J., Cerf-Bensussan, N., Gaboriau-Routhiau, V., van de Guchte, M., Maguin, E., Genome sequence of candidatus arthromitus sp. strain SFB-Mouse-NL, a commensal bacterium with a key role in postnatal maturation of gut immune functions. Genome Announc, 2(4), 2014.
74. [74] Caselli, M., Cassol, F., Gentili, V., Di Luca, D., Genome sequences of segmented filamentous bacteria in animals: implications for human research. Gut Microbes 3:5 (2012), 401–405.
75. [75] Pamp, S.J., Harrington, E.D., Quake, S.R., Relman, D.A., Blainey, P.C., Single-cell sequencing provides clues about the host interactions of segmented filamentous bacteria (SFB). Genome Res. 22:6 (2012), 1107–1119.
76. [76] Prakash, T., Oshima, K., Morita, H., Fukuda, S., Imaoka, A., Kumar, N., Sharma, V.K., Kim, S.W., Takahashi, M., Saitou, N., Taylor, T.D., Ohno, H., Umesaki, Y., Hattori, M., Complete genome sequences of rat and mouse segmented filamentous bacteria, a potent inducer of th17 cell differentiation. Cell Host Microbe 10:3 (2011), 273–284.
77. [77] Flannigan, K.L., Ngo, V.L., Geem, D., Harusato, A., Hirota, S.A., Parkos, C.A., Lukacs, N.W., Nusrat, A., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Gewirtz, A.T., Denning, T.L., IL-17A-mediated neutrophil recruitment limits expansion of segmented filamentous bacteria. Mucosal. Immunol., 2016, 10.1038/mi.2016.80.
78. [78] Paun, A., Yau, C., Danska, J.S., Immune recognition and response to the intestinal microbiome in type 1 diabetes. J. Autoimmun. 71 (2016), 10–18.
79. [79] Scott, F.W., Pound, L.D., Patrick, C., Eberhard, C.E., Crookshank, J.A., Where genes meet environment-integrating the role of gut luminal contents, immunity and pancreas in type 1 diabetes. Transl. Res. 179 (2017), 183–198.
80. [80] Umenai, T., Hirai, H., Shime, N., Nakaya, T., Asahara, T., Nomoto, K., Kita, M., Tanaka, Y., Imanishi, J., Eradication of the commensal intestinal microflora by oral antimicrobials interferes with the host response to lipopolysaccharide. Eur. J. Clin. Microbiol. Infect. Dis. 29:6 (2010), 633–641.
81. [81] Haileselassie, Y., Navis, M., Vu, N., Qazi, K.R., Rethi, B., Sverremark-Ekstrom, E., Lactobacillus reuteri and Staphylococcus aureus differentially influence the generation of monocyte-derived dendritic cells and subsequent autologous T cell responses. Immun. Inflamm. Dis. 4:3 (2016), 315–326.
82. [82] Dolpady, J., Sorini, C., Di Pietro, C., Cosorich, I., Ferrarese, R., Saita, D., Clementi, M., Canducci, F., Falcone, M., Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-Dioxygenase-Enriched tolerogenic intestinal environment. J. Diabetes Res., 2016, 2016, 7569431.
83. [83] Livanos, A.E., Greiner, T.U., Vangay, P., Pathmasiri, W., Stewart, D., McRitchie, S., Li, H., Chung, J., Sohn, J., Kim, S., Gao, Z., Barber, C., Kim, J., Ng, S., Rogers, A.B., Sumner, S., Zhang, X.S., Cadwell, K., Knights, D., Alekseyenko, A., Backhed, F., Blaser, M.J., Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. Nat. Microbiol., 1(11), 2016, 16140.
84. [84] Costa, F.R., Francozo, M.C., de Oliveira, G.G., Ignacio, A., Castoldi, A., Zamboni, D.S., Ramos, S.G., Camara, N.O., de Zoete, M.R., Palm, N.W., Flavell, R.A., Silva, J.S., Carlos, D., Gut microbiota translocation to the pancreatic lymph nodes triggers NOD2 activation and contributes to T1D onset. J. Exp. Med. 213:7 (2016), 1223–1239.
85. [85] Hansen, C.H., Krych, L., Buschard, K., Metzdorff, S.B., Nellemann, C., Hansen, L.H., Nielsen, D.S., Frokiaer, H., Skov, S., Hansen, A.K., A maternal gluten-free diet reduces inflammation and diabetes incidence in the offspring of NOD mice. Diabetes 63:8 (2014), 2821–2832.
86. [86] Marietta, E.V., Gomez, A.M., Yeoman, C., Tilahun, A.Y., Clark, C.R., Luckey, D.H., Murray, J.A., White, B.A., Kudva, Y.C., Rajagopalan, G., Low incidence of spontaneous type 1 diabetes in non-obese diabetic mice raised on gluten-free diets is associated with changes in the intestinal microbiome. PLoS One, 8(11), 2013, e78687.
87. [87] Greer, R.L., Dong, X., Moraes, A.C., Zielke, R.A., Fernandes, G.R., Peremyslova, E., Vasquez-Perez, S., Schoenborn, A.A., Gomes, E.P., Pereira, A.C., Ferreira, S.R., Yao, M., Fuss, I.J., Strober, W., Sikora, A.E., Taylor, G.A., Gulati, A.S., Morgun, A., Shulzhenko, N., Akkermansia muciniphila mediates negative effects of IFNgamma on glucose metabolism. Nat. Commun., 7, 2016, 13329.
88. [88] Mikkelsen, K.H., Frost, M., Bahl, M.I., Licht, T.R., Jensen, U.S., Rosenberg, J., Pedersen, O., Hansen, T., Rehfeld, J.F., Holst, J.J., Vilsboll, T., Knop, F.K., Effect of antibiotics on gut microbiota, gut hormones and glucose metabolism. PLoS One, 10(11), 2015, e0142352.
89. [89] Amarri, S., Benatti, F., Callegari, M.L., Shahkhalili, Y., Chauffard, F., Rochat, F., Acheson, K.J., Hager, C., Benyacoub, J., Galli, E., Rebecchi, A., Morelli, L., Changes of gut microbiota and immune markers during the complementary feeding period in healthy breast-fed infants. J. Pediatr. Gastroenterol. Nutr. 42:5 (2006), 488–495.
90. [90] Endesfelder, D., Engel, M., Davis-Richardson, A.G., Ardissone, A.N., Achenbach, P., Hummel, S., Winkler, C., Atkinson, M., Schatz, D., Triplett, E., Ziegler, A.G., zu Castell, W., Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome, 4, 2016, 17.
91. [91] Clausen, T.D., Bergholt, T., Bouaziz, O., Arpi, M., Eriksson, F., Rasmussen, S., Keiding, N., Lokkegaard, E.C., Broad-spectrum antibiotic treatment and subsequent childhood type 1 diabetes: a nationwide danish cohort study. PLoS One, 11(8), 2016, e0161654.
92. [92] Gevers, D., Kugathasan, S., Denson, L.A., Vazquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S.J., Yassour, M., Morgan, X.C., Kostic, A.D., Luo, C., Gonzalez, A., McDonald, D., Haberman, Y., Walters, T., Baker, S., Rosh, J., Stephens, M., Heyman, M., Markowitz, J., Baldassano, R., Griffiths, A., Sylvester, F., Mack, D., Kim, S., Crandall, W., Hyams, J., Huttenhower, C., Knight, R., Xavier, R.J., The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 15:3 (2014), 382–392.
93. [93] Buffie, C.G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., Ubeda, C., Xavier, J., Pamer, E.G., Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 80:1 (2012), 62–73.
94. [94] Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., Burcelin, R., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:6 (2008), 1470–1481.
95. [95] Markle, J.G., Frank, D.N., Mortin-Toth, S., Robertson, C.E., Feazel, L.M., Rolle-Kampczyk, U., von Bergen, M., McCoy, K.D., Macpherson, A.J., Danska, J.S., Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339:6123 (2013), 1084–1088.
96. [96] Vaughn, B.P., Vatanen, T., Allegretti, J.R., Bai, A., Xavier, R.J., Korzenik, J., Gevers, D., Ting, A., Robson, S.C., Moss, A.C., Increased intestinal microbial diversity following fecal microbiota transplant for active crohn's disease. Inflamm. Bowel Dis. 22:9 (2016), 2182–2190.
97. [97] Lopez, J., Grinspan, A., Fecal microbiota transplantation for inflammatory bowel disease. Gastroenterol. Hepatol. (N Y) 12:6 (2016), 374–379.
98. [98] Ishikawa, D., Sasaki, T., Osada, T., Kuwahara-Arai, K., Haga, K., Shibuya, T., Hiramatsu, K., Watanabe, S., Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. Inflamm. Bowel Dis. 23:1 (2017), 116–125.
99. [99] Mittal, C., Miller, N., Meighani, A., Hart, B.R., John, A., Ramesh, M., Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lymphoma. Bone Marrow Transplant., 50(7), 2015, 1010.
100. [100] Blackburn, L.M., Bales, A., Caldwell, M., Cordell, L., Hamilton, S., Kreider, H., Fecal microbiota transplantation in patients with cancer undergoing treatment. Clin. J. Oncol. Nurs. 19:1 (2015), 111–114.
101. [101] Kulecka, M., Paziewska, A., Zeber-Lubecka, N., Ambrozkiewicz, F., Kopczynski, M., Kuklinska, U., Pysniak, K., Gajewska, M., Mikula, M., Ostrowski, J., Prolonged transfer of feces from the lean mice modulates gut microbiota in obese mice. Nutr. Metab. (Lond), 13(1), 2016, 57.
102. [102] Vrieze, A., Van Nood, E., Holleman, F., Salojarvi, J., Kootte, R.S., Bartelsman, J.F., Dallinga-Thie, G.M., Ackermans, M.T., Serlie, M.J., Oozeer, R., Derrien, M., Druesne, A., VanHylckamaVlieg, J.E., Bloks, V.W., Groen, A.K., Heilig, H.G., Zoetendal, E.G., Stroes, E.S., deVos, W.M., Hoekstra, J.B., Nieuwdorp, M., Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:4 (2012), 913–916 e917.
103. [103] van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., Visser, C.E., Kuijper, E.J., Bartelsman, J.F., Tijssen, J.G., Speelman, P., Dijkgraaf, M.G., Keller, J.J., Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368:5 (2013), 407–415.
104. [104] Girotra, M., Garg, S., Anand, R., Song, Y., Dutta, S.K., Fecal microbiota transplantation for recurrent clostridium difficile infection in the elderly: long-term outcomes and microbiota changes. Dig. Dis. Sci. 61:10 (2016), 3007–3015.
105. [105] Jalanka, J., Mattila, E., Jouhten, H., Hartman, J., de Vos, W.M., Arkkila, P., Satokari, R., Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med., 14(1), 2016, 155.
106. [106] Fischer, M., Sipe, B., Cheng, Y.W., Phelps, E., Rogers, N., Sagi, S., Bohm, M., Xu, H., Kassam, Z., Fecal microbiota transplant in severe and severe-Complicated clostridium difficile: a promising treatment approach. Gut Microbes, 0, 2016.
107. [107] Hirsch, B.E., Saraiya, N., Poeth, K., Schwartz, R.M., Epstein, M.E., Honig, G., Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect. Dis., 15, 2015, 191.
108. [108] Moayyedi, P., Surette, M.G., Kim, P.T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J.K., Kassam, Z., Reinisch, W., Lee, C.H., Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149:1 (2015), 102–109 e106.
109. [109] Stallmach, A., Lange, K., Buening, J., Sina, C., Vital, M., Pieper, D.H., Fecal microbiota transfer in patients with chronic antibiotic-refractory pouchitis. Am. J. Gastroenterol. 111:3 (2016), 441–443.
110. [110] Ott, S.J., Waetzig, G.H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J.A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., Rosenstiel, P., Efficacy of sterile fecal filtrate transfer for treating patients with clostridium difficile infection. Gastroenterology, 151, 2016 epub before print.
111. [111] Rautava, S., Early microbial contact, the breast milk microbiome and child health. J. Dev. Orig. Health Dis. 7:1 (2015), 5–14.
112. [112] Goedert, J.J., Hua, X., Yu, G., Shi, J., Diversity and composition of the adult fecal microbiome associated with history of cesarean birth or appendectomy: analysis of the American Gut Project. EBioMedicine 1:2–3 (2014), 167–172.
113. [113] Cacho, N., Neu, J., Manipulation of the intestinal microbiome in newborn infants. Adv Nutr. 5:1 (2014), 114–118.
114. [114] Reikvam, D.H., Erofeev, A., Sandvik, A., Grcic, V., Jahnsen, F.L., Gaustad, P., McCoy, K.D., Macpherson, A.J., Meza-Zepeda, L.A., Johansen, F.E., Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS One, 6(3), 2011, e17996.
115. [115] Tietze, K., Dalpke, A., Morath, S., Mutters, R., Heeg, K., Nonnenmacher, C., Differences in innate immune responses upon stimulation with gram-positive and gram-negative bacteria. J. Periodontal Res. 41:5 (2006), 447–454.
116. [116] Dogi, C.A., Galdeano, C.M., Perdigon, G., Gut immune stimulation by non pathogenic Gram(+) and Gram(−) bacteria: comparison with a probiotic strain. Cytokine 41:3 (2008), 223–231.
117. [117] Skovbjerg, S., Martner, A., Hynsjo, L., Hessle, C., Olsen, I., Dewhirst, F.E., Tham, W., Wold, A.E., Gram-positive and gram-negative bacteria induce different patterns of cytokine production in human mononuclear cells irrespective of taxonomic relatedness. J. Interferon Cytokine Res. 30:1 (2010), 23–32.
118. [118] De Palma, G., Cinova, J., Stepankova, R., Tuckova, L., Sanz, Y., Pivotal Advance: bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. J. Leukoc. Biol. 87:5 (2010), 765–778.
119. [119] Jin, Y., Chen, X., Podolsky, R., Hopkins, D., Makala, L.H., Muir, A., She, J.X., APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes. Clin. Immunol. 130:3 (2009), 272–279.
120. [120] Manirarora, J.N., Kosiewicz, M.M., Parnell, S.A., Alard, P., APC activation restores functional CD4(+)CD25(+) regulatory T cells in NOD mice that can prevent diabetes development. PLoS One, 3(11), 2008, e3739.
121. [121] Patel, R., DuPont, H.L., New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin. Infect. Dis. 60:Suppl. 2 (2015), S108–121.
122. [122] Knip, M., Siljander, H., The role of the intestinal microbiota in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 12:3 (2016), 154–167.
123. [123] Kolb, H., von Herrath, M., Immunotherapy for type 1 diabetes: why do current protocols not halt the underlying disease process?. Cell Metab. 25:2 (2016), 233–241.